Sign in

You're signed outSign in or to get full access.

Manuel Smithers

Research Analyst at Deutsche Bank Ag\

No public information is available regarding Manuel Smithers as an analyst at Deutsche Bank. There are no verifiable details about his title, companies covered, performance metrics, career timeline, or professional credentials in reliable sources. As a result, a comprehensive professional profile cannot be provided at this time.

Manuel Smithers's questions to Moderna (MRNA) leadership

Question · Q3 2024

On behalf of Emmanuel Smithers, a question was asked about the expected speed of the market's transition to a flu/COVID combo vaccine and for an update on COVID-related litigation, particularly the recent GSK lawsuit.

Answer

President Stephen Hoge stated that a market transition to the combo vaccine is not expected in 2025 due to the timing of flu contracting, but the company is bullish on the long-term opportunity for 2026 and beyond. CEO Stéphane Bancel declined to comment on the merits of the GSK case but noted the company is prepared to defend itself.

Ask follow-up questions

Fintool

Fintool can predict Moderna logo MRNA's earnings beat/miss a week before the call